Dexmedetomidine Increases Hippocampal Phosphorylated Extracellular Signal–regulated Protein Kinase 1 and 2 Content by an α2-Adrenoceptor–independent Mechanism
- 1 March 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 108 (3) , 457-466
Abstract
DEXMEDETOMIDINE is a potent and highly selective agonist of the α2-adrenergic receptors with a broad spectrum of actions on the human brain, including clinical sedation, anesthetic-sparing effects, and analgesia.1–5 Besides its action at α2-adrenergic receptors, dexmedetomidine also exhibits some affinity for imidazoline binding sites.6–8 Recent experimental work indicates that dexmedetomidine also exhibits more long-term effects on the brain, such as neuroprotection against ischemic injury.9–14 We have shown that dexmedetomidine reduces the severity of excitotoxic brain injury in the perinatal period in mice.9 Well-designed experiments performed in knockout animals have shown that this effect is mediated by the activation of the α2A-adrenoceptor subtype.10,11 These neuroprotective properties of dexmedetomidine most likely proceed via activation of intracellular signaling cascades, while an indirect effect through a reduction in the release of glutamate or catecholamines cannot be ruled out.12,13 We have shown that dexmedetomidine preconditions brain tissue against ischemic cell death and caspase-3 expression in hippocampal slices subjected to oxygen glucose deprivation.14 This effect is mediated in part by an increase in phosphorylation of focal adhesion kinase, a nonreceptor tyrosine kinase coupling rapid events such as ligand–receptor interactions, or action potential propagation, to long-lasting changes in synaptic plasticity.15 Also, dexmedetomidine exerts synergistic neuroprotective effects with xenon that have been observed 30 days after ischemic injury.16Keywords
This publication has 44 references indexed in Scilit:
- The Effects of Dexmedetomidine on Perinatal Excitotoxic Brain Injury are Mediated by the α2A-Adrenoceptor SubtypeAnesthesia & Analgesia, 2006
- Sole Use of Dexmedetomidine Has Limited Utility for Conscious Sedation during Outpatient ColonoscopyAnesthesiology, 2005
- Developmental Age Influences the Effect of Epidural Dexmedetomidine on Inflammatory Hyperalgesia in Rat PupsAnesthesiology, 2005
- Dexmedetomidine as a Total Intravenous Anesthetic AgentAnesthesiology, 2004
- The Role of the α2-Adrenoceptor Agonist Dexmedetomidine in Postsurgical Sedation in the Intensive Care UnitJournal of Intensive Care Medicine, 2003
- Effects of α2-Adrenoceptor Agonists on Perinatal Excitotoxic Brain InjuryAnesthesiology, 2002
- Clinical Uses of α2-Adrenergic AgonistsAnesthesiology, 2000
- [3H]Dexmedetomidine, an α2-adrenoceptor agonist, detects a novel imidazole binding site in adult rat spinal cordEuropean Journal of Pharmacology, 1996
- Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I-receptors in the guinea pigEuropean Journal of Pharmacology, 1991
- Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonistEuropean Journal of Pharmacology, 1988